19-Feb-2010
Novavax elects Stanley Erck as executive chairman
Contract Services | Biotechnology | R and D | Pharmaceuticals | Vaccines |
The board of directors of Novavax, a US clinical-stage biotechnology firm, has elected Stanley Erck as executive chairman.
Erck was formerly chief executive of Iomai Corporation, leading the company through an IPO and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate.
He has also worked for immunology firm Procept, Integrated Genetics (now Genzyme), and Baxter International.